Literature DB >> 6460383

Plasma exchange and immune complex diseases: the predictability of immune complexes removal to clinical response.

M Valbonesi, S Garelli, F Montani, F Manca, S Cantarella.   

Abstract

58 patients were treated by discontinuous flow plasma exchange because of an immune complex (IC) disease. 41 patients who had a high level of circulating IC prior to plasmapheresis showed both clinical and immunochemical evidence of improvement with plasma exchange. Only 2 patients with a high level of IC did not improve after therapy: these patients suffered from multiple sclerosis and idiopathic thrombocytopenic purpura, respectively. Prior to PE therapy the level of circulating IC in 15 patients was within the normal range, when measured according to Manca et al. In this group none of the patients worsened after therapy, whereas 8 patients showed an objective improvement. The positive correlation between IC removal and clinical results suggests that patients with a high level of circulating IC are most likely to benefit from apheretic treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460383     DOI: 10.1111/j.1423-0410.1982.tb01066.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  1 in total

1.  Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.

Authors:  Jonathan Herskovitz; Josiah Ryman; Theingi Thway; Stephanie Lee; Lei Zhou; Narendra Chirmule; Bernd Meibohm; Vibha Jawa
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.